Article

(disponible) - Article
The economic cost of Alzheimer 's disease : family or public health burden? / CASTRO, Diego M.. ; [et al].
Dementia & neuropsychologia, 2010, vol. 4 (4 (dec.)), p. 262-267.

http://www.demneuropsy.com.br/imageBank/PDF/v4n4a03.pdf... (30-01-2012)

Lieux géographiques
: Amérique du Sud

Mots-clés principaux
:
Maladie d'Alzheimer
Coûts de la santé
Aspect économique
Coûts sociaux


Résumé :

Alzheimer's disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options.

Langue : Anglais
Doc n° : 28924
NumRec : 6070703
 

       

  Copier Permanent URL de cette page Ajouter cette page

     

disponible
Réserver
Pour réserver ce document, vous devez d'abord vous connecter


Aller vers :   IUGM    Fondation IUGM   Centre de recherche IUGM